Full year report 2012 - Nobel Biocare Corporate
Full year report 2012 - Nobel Biocare Corporate
Full year report 2012 - Nobel Biocare Corporate
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Dividend – The Board of Directors proposes a dividend of CHF 0.20 per registered share (2011: CHF0.15) reflecting the improved net profit of the <strong>year</strong> and a payout ratio of 44%. It is planned to pay thisdividend out of reserves and in a shareholder-friendly way without deduction of withholding tax. Thepayment date for this dividend, if approved by the AGM, is set for 8 April 2013 (ex-dividend date: 3 April2013, record date: 5 April 2013).Addition to the Board of Directors – To drive the implementation of <strong>Nobel</strong> <strong>Biocare</strong>’s strategy, one ofthe priorities of the Board of Directors has been to broaden and strengthen its operational andmanagement expertise, in particular in the area of medical technology and implant-based toothrestoration. Following this priority, the Board of Directors proposes Franz Maier to be elected as aMember of the Board. Franz Maier brings a successful track record of over 20 <strong>year</strong>s in both functionaland general management positions, most recently as an Executive Vice President Sales and Member ofthe Executive Board of Straumann in the medical devices and biotechnology industry. All existingMembers of the Board stand for re-election.Outlook<strong>Nobel</strong> <strong>Biocare</strong> believes that the market conditions for 2013 will remain difficult, similar to <strong>2012</strong>.In this environment, the Company targets to modestly build market share and deliver modest revenuegrowth. Based on this and the initiated measures, and barring any unforeseen events, <strong>Nobel</strong> <strong>Biocare</strong>expects to deliver an EBIT margin improvement of 50 to100 bps at constant exchange rates (CER).<strong>Nobel</strong> <strong>Biocare</strong> is moving from ‘rebuilding’ to a phase of continual performance improvements. Withinthe next 3 to 5 <strong>year</strong>s, assuming markets improve beyond 2013 to modest mid-single digit growth, <strong>Nobel</strong><strong>Biocare</strong> targets growing at least in line with the market and to improve EBIT margin also continuallybetween 50 to 100 bps per annum at constant exchange rates.<strong>Nobel</strong> <strong>Biocare</strong> (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dentalsolutions. As a complete solutions provider, <strong>Nobel</strong> <strong>Biocare</strong> offers the most comprehensive range of solutionsfrom tooth to root, for single tooth to fully edentulous indications. The solutions portfolio covers dentalimplants (including the key brands <strong>Nobel</strong>Active ® , Brånemark System ® and <strong>Nobel</strong>Replace ® , individualizedprosthetics and equipment (<strong>Nobel</strong>Procera ® , guided surgery solutions and biomaterials). <strong>Nobel</strong> <strong>Biocare</strong> hasapproximately 2’500 employees and recorded revenue of EUR 580.5 million in <strong>2012</strong>. The company is headquarteredin Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan,Sweden, and the US. <strong>Nobel</strong> <strong>Biocare</strong> has 34 direct sales organizations.Further information is available from:Süha DemokanInvestor and <strong>Corporate</strong> RelationsTel: +41 43 211 42 30, +41 79 430 81 46suha.demokan@nobelbiocare.com<strong>Full</strong> <strong>year</strong> <strong>report</strong> <strong>2012</strong>6/21
Change language